|
Cambridge, MA (I-Newswire) March 16, 2011 - Cambridge, MA -- Semprus BioSciences today announced its Chief Technology Officer Christopher Loose, Ph.D., will present the company's groundbreaking data results on its non-fouling Semprus Platform at the Society of Interventional Radiology's (SIR) 36th Annual Scientific Meeting in Chicago, Ill., on Monday, March 28, 2011.
Dr. Loose will present Semprus' data on its single-surface modification that demonstrate simultaneous reduction of microbial and platelet adhesion over multiple months. These data showcase the technology's three distinctive aspects: its dual-functionality, its ability to work in blood products, and its long-term durational advantages over existing surface and coating technologies.
SIR's Annual Meeting is a recognized forum for peer-reviewed presentations of new research by interventional radiologists and allied scientists from around the world. It provides a host of news and educational opportunities ranging from scientific presentations and news conferences to hands-on workshops and technical exhibits.
Semprus BioSciences is a venture-backed biomedical company with a dual mission: to provide complication-free medical devices designed to preserve patients' long-term health and quality-of-life and to contribute to healthcare cost efficiencies. The company's current focus is to develop a vascular access catheter with the first single surface modification that is designed to simultaneously reduce microbial adherence and thrombus accumulation over the life of the device. The company spun out of the labs of biomedical researcher and Massachusetts Institute of Technology (MIT) Professor Robert Langer, Sc.D., in 2007.
"It's a great privilege for us to present our novel technology at SIR's annual meeting," said Chief Executive Officer David L. Lucchino. "We are very proud of our technology and excited to highlight the aspects that distinguish it from other surface and coating technologies currently on the market."
Dr. Loose will present at the Venous Access/Thrombolysis Scientific Session on Monday, March 28, at 8:30 a.m. in Room W181C, McCormick Place West Building.
About Semprus BioSciences
Semprus BioSciences is a venture-backed biomedical company headquartered in Cambridge, Massachusetts. The company's innovative, multi-faceted Semprus technology signifies a breakthrough in medical device technology. Its current focus is to develop a vascular access catheter with the first single surface modification that is designed to simultaneously reduce microbial adherence and thrombus accumulation over the life of the device. In December 2010, the company completed an $18 million Series B financing co-led by SR One, the corporate venture capital arm of GlaxoSmithKline, and Foundation Medical Partners (FMP), a national healthcare venture capital investment firm with a strategic relationship with Cleveland Clinic. Combined with previous financing rounds, Semprus has raised a total of $28.5 million in equity.
Visit http://www.semprusbio.com for additional information.
Semprus BioSciences won Frost & Sullivan’s “2010 North American Enabling Technology of the Year Award for Surface in Functionalization Technologies” for its Semprus Platform in December 2010.
Semprus BioSciences was selected as one of “50 Companies to Watch” by Medical Devices & Diagnostics Industry magazine in June 2010.
Contact: Michael Devine
michael.devine@semprusbio.com
617.577.7755 ext. 202
Holly P. Glass
holly.glass@semprusbio.com
571.243.1952
About Semprus BioSciences:
Semprus BioSciences, headquartered in Cambridge, Massachusetts, is a venture-backed biomedical company with a dual mission: to provide complication-free medical devices designed to preserve patients’ long-term health and quality-of-life and to contribute to health care cost efficiencies. Our innovative, multi-faceted approach to durable surface modifications signifies a breakthrough in medical device technology. Our current focus is to enable the first permanently dual-functional (anti-colonization and anti-thrombogenic) vascular access catheter with a single surface modification.
Founded out of the Massachusetts Institute of Technology's Langer Lab, the company has developed the next-generation biofunctional surface platform – which is focused on achieving clinical benefits that far exceed current market offerings containing silver, heparin, and antibiotic coatings. Through covalent chemical bonding of our Semprus Surfaces™, a permanent non-leaching biomaterial modification to the device surface, our technology is expected to vastly improve patient outcomes by preventing serious medical complications, such as infection, blood clots, improper healing, and cell overgrowth. We have assembled a world class product development team – scientists, industry executives and clinical experts – who specialize in reducing such complications at the confluence of the human body and implantable devices.
In December 2010, Semprus BioSciences completed an $18 million Series B financing round co-led by SR One, the corporate venture capital arm of GlaxoSmithKline, and Foundation Medical Partners (FMP), a national healthcare venture capital investment firm with a strategic relationship with Cleveland Clinic. Prior to this, Semprus completed a Series A financing round co-led by a venture capital firm focused on building next-generation life science companies, and Pangaea Ventures, a venture capital firm that invests in advanced materials, energy, biomedical, and environmental technology companies, in December 2008. This funding came on the heels of our $2.5 million seed capital raised in 2007.
Additionally, we have worldwide licenses secured from MIT and the University of Washington, and hold numerous proprietary intellectual property filings. Our laboratory and office complex is located in Kendall Square, Cambridge's innovative biomedical center, and employs 27 full-time professionals.
Company Contact Information
Semprus BioSciences
Michael Devine
One Kendall Square
Building 1400W, 1st Floor
02139
Phone : 6175777755
|
